Inhibition of protein tyrosine/mitogen-activated protein kinase phosphatase activity is associated with D2 dopamine receptor supersensitivity in a rat model of Parkinson's disease

Molecular Pharmacology

Volumn 62, Issue 6, 2002, Pages 1356-1363

  Zhen, Xuechu ^a   Torres, Claudio ^a   Cai, Guoping ^a   Friedman, Eitan ^a  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OXIDOPAMINE; PROTEIN TYROSINE PHOSPHATASE; QUINPIROLE; SPIPERONE; VANADIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DRUG ANTAGONISM; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; RAT;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; OXIDOPAMINE; PARKINSON DISEASE; PC12 CELLS; PHOSPHORYLATION; PROTEIN-TYROSINE-PHOSPHATASE; QUINPIROLE; RATS; RECEPTORS, DOPAMINE D2; SYMPATHOLYTICS; TYROSINE; VANADATES;

EID: 0036893701     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.6.1356     Document Type: Article

References (32)

1. Abrous DN, Rivet JM, Le Moral M, and Herman JP (1990) Similar post-lesion receptor readjustments following the unilateral 6-OHDA lesion of the dopaminergic mesotelencephalic system in neonatal and adult rats. Brain Res 526:195-202.
2. Agid Y (1991) Parkinson's disease: Pathophysiology. Lancet 337:1321-1323.
3. Arnt J and Hyttel J (1984) Differential inhibition by dopamine D-1 and D-2 antagonist of circling behavioral induced by dopamine agonist in rats with unilateral 6-OHDA lesions. Eur J Pharmacol 102:349-354.
4. Bennecib M, Gonsphg CX, Iqbal IG, and Iqbal K (2000) Role of protein phosphatse-2A and 1 in the regulation of GSK-3, CDK5 and CDC2 and the phosphorylation of tau in rat forebrain. FEBS Lett 485:87-93.
5. Bezard E and Gross CC (1998) Compensatory mechanisms in experimental and human parkisonism: Towards a dynamic approach. Prog Neurobiol 55:93-116.
6. Blandini F, Nappi G, Tassorelli C, and Martignoni E (2000) Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62:63-88.
7. Blum D, Torch S, Lambeng N, Nissou MF, Benabid AL, Sadoul R, and Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65:135-172.
8. Brondello JM, Pouyssegur, and Mckenzie FR (1999) Reduced MAP kinase phosphatase-1 degradation after p42/p44 MAPK-dependent phosphorylation. Science (Wash DC) 286:2514-2517.
9. Butkerait P, Wang HY, E Friedman E (1994) Increase in guanine nucleotide binding to striatal G proteins is associated with dopamine receptor supersensitivity. J Pharmacol Exp Ther 271:422-428.
10. Cai GP, Zhen XC, Uryu K, and Friedman E (2000) Activation of extracellular signal-regulated protein kinase is associated with sensitized locomotor response to D2 dopamine receptor stimulation in unilateral 6-OHDA-lesioned rats. J Neurosci 20:1849-1867.
11. Carey RJ (1986) Conditioned rotational behavior in rats with unilateral 6-hydroxydopamine lesion of the substantia nigra. Brain Res 365:379-382.
12. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA, Dawson VL, and Dawson TM (2001) Parkin ubiquitinates the α-synuclein-interacting protein, synphilin-1: Implication for Lewy-body formation in Parkinson disease. Nat Med 7:1144-1150.
13. Girault JA, Siciliano JC, Robel L, and Herve D (1992) Stimulation of protein-tyrosine phosphorylation in rat striatum after lesion of dopamine neurons or chronic neuroleptic treatment. Proc Natl Acad Sci USA 89:2769-2733.
14. Keyse SM (1998) Protein phosphatases and the regulation of MAP kinase activity, Cell Dev Biol 9:143-152.
15. Kostrzewa RM (1995) Dopamine receptor supersensitivity. Neurosci Biobehav Rev 19:1-17.
16. Mileson BE, Lewis MH, and Mailman RB (1991) Dopamine receptor "supersensitivity" occurring without receptor up-regulation. Brain Res 561:1-10.
17. Misra-Press A, Rim CS, Yao H, Roberson MS, and Stork PJS (1995) A novel mitogenactivated protein kinase phosphatase. J Biol Chem 270:14587-14596.
18. 2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J Neurol Sci 86:291-306.
19. Radja F, Mansari M, Soghomonian JJ, Dewar KM, Ferron A, Reader TA, and Descarries L (1993) Changes of D1 and D2 receptors in adult rat neostriatum after neonatal dopamine denervation: Quantitative data from ligand binding, in situ hybridization and iontophoresis. Neuroscience 57:635-648.
20. Rubinstein M, Muschietti JP, Gershanik O, Flawia MM, and Stefano FJE (1990) Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice. J Pharmacol Exp Ther 252:810-816.
21. Sandstrom MI and Bruno JP (1997) Sensitivity to the motoric effects of a dopamine receptor antagonist differs as a function of age at the time of dopamine depletion. Dev Psychobiol 30:293-300.
22. Schwarting RKW and Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research: Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275-331.
23. Sequeira S (2001) α-Synuclein degradation by parkin is impaired in Parkinson's disease. Trends Neurosci 24:569.
24. Soriano MA, Tessier M, Certa U, and Gill R (2000) Parallel gene expression monitoring using oligonucleotide probe arrays of multiple transcripts with an animal model of focal ischemia. J Cereb Blood Flow Metab 20:1045-1055.
25. Stoker A and Dutta R (1998) Protein tyrosine phosphatases and neural development. Bioessays 20:463-472.
26. Tonks NK (1993) Characterization of protein (tyrosine) phosphatases, in Protein Phosphorylation: A Practical Approach (Hardie ed), pp 231-252. D. G. IRL Press, San Diego.
27. Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:108-110.
28. 2 dopamine receptors induce mitogen-activated protein kinase and camp response element-binding protein phosphorylation in neurons. Proc Natl Acad Sci 96:11607-1161.
29. Wiessner C, Neumann-Haefelin T, Vogel P, Back T, and Hossmann KA (1995) Transient forebrain ischemia induces an immediate-early gene encoding the mitogen-activated protein kinase phosphatase 3CH134 in the adult rat brain. Neuroscience 64:959-966.
30. Winter C, Schenkel J, Zimmermann M, and Herdegen T (1998) MAP kinase phosphatase 1 is expressed and enhanced by FK506 in surviving mamillary, but not degenerating nigral neurons following axotomy. Brain Res 801:198-205.
31. 1 dopamine receptor function via selective inhibition of protein phosphatase 1 pathway in rabbit frontal cortex. J Neurosci 21:9160-9167.
32. Zhen XC, Zhang J, Johnson GP, and Friedman E (2001b) D4 dopamine receptor differentially regulates Akt/nuclear factor-κB and extracellular signal-regulated kinase pathways in D4MN9D cells. Mol Pharm 60:867-864.